amg-337
Small moleculeexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01253707)
Timeline
Indications
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(-c5cnn(C)c5)cn34)c(=O)c2c1- Mol. weight
- 463.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3785909 ↗
- ChEMBLCHEMBL3545212 ↗
Also known as
- amg 337
- amg 337
- amg-337
- amg-337
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03132155 | Phase 2 | May 1, 2017 | NantWorks |
| NCT03147976 | Phase 2 | May 1, 2017 | NantWorks |
| NCT02344810 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Eastern Cooperative Oncology Group, ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
| NCT02096666 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2014 | Amgen |
| NCT02016534 | Phase 2 | Feb 1, 2014 | Amgen |
| NCT01253707 | Phase 1 | Dec 1, 2010 | Amgen |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 3 | 3 | 2 | 2010 |
| NantWorks | For profit | 2 | 2 | 1 | 2017 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2015 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 1 | 0 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2015 |
5 organizations
Page 1 / 1